Tosoh Bioscience, Inc.

Tosoh Bioscience, Inc., doing business as Tosoh USA, is a foreign-owned manufacturer of high-performance liquid chromatography (HPLC) testing instrumentation and hemoglobin A1C (HbA1c) diagnostic solutions that operates as a prime contractor supplying specialized clinical laboratory equipment and cost-per-reportable-result testing services to the Department of Veterans Affairs across multiple Veterans Integrated Service Networks. The company competes full-and-open on non-set-aside procurements and holds no SBA designations.

Tosoh Bioscience is headquartered in South San Francisco, California, and specializes in ion exchange HPLC-based A1C testing analyzers, reagents, test cartridges, and supplies for diabetes diagnosis and management across federal healthcare networks. Recent work includes a $3.5 million single-award Blanket Purchase Agreement with Veterans Integrated Service Network 17 (awarded May 1, 2026, through April 30, 2031) for hemoglobin A1C testing products and services; a $3.5 million Indefinite Delivery Contract with Veterans Integrated Service Network 22 (awarded March 18, 2026, through March 17, 2031) for HbA1c analyzers and cost-per-test laboratory services across four VA medical centers in California and Arizona; and a $2.09 million BPA with Veterans Integrated Service Network 16 (awarded January 1, 2026, through December 31, 2030) for ion exchange HPLC A1C testing instrumentation, reagents, and supplies.

Customer concentration is heavily skewed toward the Department of Veterans Affairs. The top five customers by potential value account for approximately 70% of combined potential value, anchored by Veterans Integrated Service Network 12 ($129.2 million across 146 awards), Veterans Integrated Service Network 15 ($35.5 million across 55 awards), Veterans Integrated Service Network 16 ($16.4 million across 296 awards), Veterans Integrated Service Network 4 ($13.9 million across 208 awards), and Veterans Integrated Service Network 17 ($12.6 million across 104 awards). By award count, Veterans Integrated Service Network 16 leads at 296 awards, followed by Veterans Integrated Service Network 4 at 208 awards and Veterans Integrated Service Network 23 at 173 awards, reflecting a high-volume, low-dollar-per-order transactional pattern characteristic of clinical laboratory supply procurement.

Tosoh Bioscience holds significant positions on two primary federal vehicles. The Federal Supply Schedule V797P7020A carries 974 task orders valued at $74.2 million in combined potential value, and the Critical Analyzers, Laboratory (FSS-66-III) GSA Schedule carries 936 task orders valued at $73.6 million. The company places all work through these GSA Schedule vehicles and single-award or multiple-award blanket purchase agreements issued under them across individual VISNs. Recent awards demonstrate consistent ordering: VISN 17 A1C CPRR BPAs, VISN 4 A1C testing delivery orders across nine Pennsylvania and Delaware medical centers, VISN 6 LAB A1C cost-per-reportable-result calls, and VISN 23 hemoglobin testing BPAs across Nebraska, Iowa, Minnesota, and South Dakota facilities.

Activity across the federal footprint shows stability. Over the past five years, awards averaged 62 per year (ranging from 55 in 2023 to 75 in 2022), with 57 awards in 2026 year-to-date. Combined potential value stands at $296.6 million with $75.6 million obligated. The vendor faces a recompete cliff of $3.3 million in awards completing within the next twenty-four months, reflecting the rolling nature of annual option-period renewals and facility-specific task orders that characterize VA clinical laboratory procurement.

Tosoh Bioscience operates exclusively as a prime contractor with no subcontract relationships noted across its federal portfolio. The company's award footprint is entirely within non-set-aside, firm fixed-price procurements on GSA Schedules and VA-issued IDIQs, positioning it as a specialized sole-source or preferred supplier for hemoglobin A1C testing capabilities where clinical laboratory specifications and equipment validation requirements create high switching costs and sustained demand across the veteran healthcare system.